LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: A Methodology for Classifying Root Causes of Outbreaks of Legionnaires’ Disease: Deficiencies in Environmental Control and Water Management

    Clopper, Benjamin R / Kunz, Jasen M / Salandy, Simone W / Smith, Jessica C / Hubbard, Brian C / Sarisky, John P

    Microorganisms. 2021 Jan. 01, v. 9, no. 1

    2021  

    Abstract: We piloted a methodology for collecting and interpreting root cause—or environmental deficiency (ED)—information from Legionnaires’ disease (LD) outbreak investigation reports. The methodology included a classification framework to assess common failures ...

    Abstract We piloted a methodology for collecting and interpreting root cause—or environmental deficiency (ED)—information from Legionnaires’ disease (LD) outbreak investigation reports. The methodology included a classification framework to assess common failures observed in the implementation of water management programs (WMPs). We reviewed reports from fourteen CDC-led investigations between 1 January 2015 and 21 June 2019 to identify EDs associated with outbreaks of LD. We developed an abstraction guide to standardize data collection from outbreak reports and define relevant parameters. We categorized each ED according to three criteria: ED type, WMP-deficiency type, and source of deficiency. We calculated the prevalence of EDs among facilities and explored differences between facilities with and without WMPs. A majority of EDs identified (81%) were classified as process failures. Facilities with WMPs (n = 8) had lower prevalence of EDs attributed to plumbed devices (9.1%) and infrastructure design (0%) than facilities without WMPs (n = 6; 33.3% and 24.2%, respectively). About three quarters (72%) of LD cases and 81% of the fatalities in our sample originated at facilities without a WMP. This report highlights the importance of WMPs in preventing and mitigating outbreaks of LD. Building water system process management is a primary obstacle toward limiting the root causes of LD outbreaks. Greater emphasis on the documentation, verification, validation, and continuous program review steps will be important in maximizing the effectiveness of WMPs.
    Keywords administrative management ; classification ; data collection ; death ; design ; infrastructure ; microorganisms ; outbreak investigation ; prevalence ; water ; water management
    Language English
    Dates of publication 2021-0101
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    Note NAL-light
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms9010089
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article: A Methodology for Classifying Root Causes of Outbreaks of Legionnaires' Disease: Deficiencies in Environmental Control and Water Management.

    Clopper, Benjamin R / Kunz, Jasen M / Salandy, Simone W / Smith, Jessica C / Hubbard, Brian C / Sarisky, John P

    Microorganisms

    2021  Volume 9, Issue 1

    Abstract: We piloted a methodology for collecting and interpreting root cause-or environmental deficiency (ED)-information from Legionnaires' disease (LD) outbreak investigation reports. The methodology included a classification framework to assess common failures ...

    Abstract We piloted a methodology for collecting and interpreting root cause-or environmental deficiency (ED)-information from Legionnaires' disease (LD) outbreak investigation reports. The methodology included a classification framework to assess common failures observed in the implementation of water management programs (WMPs). We reviewed reports from fourteen CDC-led investigations between 1 January 2015 and 21 June 2019 to identify EDs associated with outbreaks of LD. We developed an abstraction guide to standardize data collection from outbreak reports and define relevant parameters. We categorized each ED according to three criteria: ED type, WMP-deficiency type, and source of deficiency. We calculated the prevalence of EDs among facilities and explored differences between facilities with and without WMPs. A majority of EDs identified (81%) were classified as process failures. Facilities with WMPs (
    Language English
    Publishing date 2021-01-01
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms9010089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Medical Costs of RSV-associated Hospitalizations and Emergency Department Visits in Children Aged <5 years: Observational Findings from the New Vaccine Surveillance Network (NVSN), 2016-2019.

    Clopper, Benjamin R / Zhou, Yingtao / Tannis, Ayzsa / Staat, Mary Allen / Rice, Marilyn / Boom, Julie A / Sahni, Leila C / Selvarangan, Rangaraj / Harrison, Christopher J / Halasa, Natasha B / Stewart, Laura S / Weinberg, Geoffrey A / Szilagyi, Peter G / Klein, Eileen J / Englund, Janet A / Rha, Brian / Lively, Joana Y / Ortega-Sanchez, Ismael R / McMorrow, Meredith L /
    Moline, Heidi L

    The Journal of pediatrics

    2024  , Page(s) 114045

    Abstract: Objective: To assess medical costs of hospitalizations and emergency department (ED) care associated with respiratory syncytial virus (RSV) disease in children enrolled in the New Vaccine Surveillance Network.: Study design: We used accounting and ... ...

    Abstract Objective: To assess medical costs of hospitalizations and emergency department (ED) care associated with respiratory syncytial virus (RSV) disease in children enrolled in the New Vaccine Surveillance Network.
    Study design: We used accounting and prospective surveillance data from six pediatric health systems to assess direct medical costs from laboratory-confirmed RSV-associated hospitalizations (n=2,007) and ED visits (n=1,267) from 2016 through 2019 among children aged <5 years. We grouped costs into categories relevant to clinical care and administrative billing practices. We examined RSV-associated medical costs by care setting using descriptive and bivariate analyses. We assessed associations between known RSV risk factors and hospitalization costs and length of stay (LOS) using chi-square tests of association.
    Results: The median cost was $7,100 (IQR: $4,006-$13,355) per hospitalized child and $503 (IQR: $387-$930) per ED visit. Eighty percent (n=2,628) of our final sample were children aged <2 years. Fewer weeks' gestational age (GA) was associated with higher median costs in hospitalized children [p<0.001, ≥37 weeks' GA: $6,840 ($3,905-$12,450); 29-36 weeks' GA: $7,721 ($4,362-$15,274); <29 w weeks' GA: $9,131 ($4,518-$19,924)]. Full-term infants accounted for 70% of the total expenditures in our sample. Almost three quarters of the healthcare dollars spent originated in children under 12 months of age; the primary age group targeted by recommended RSV prophylactics.
    Conclusions: Reducing the cost burden for RSV-associated medical care in young children will require prevention of RSV in all young children, not just high-risk infants. Newly available maternal vaccine and immunoprophylaxis products could substantially reduce RSV-associated medical costs.
    Language English
    Publishing date 2024-03-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3102-1
    ISSN 1097-6833 ; 0022-3476
    ISSN (online) 1097-6833
    ISSN 0022-3476
    DOI 10.1016/j.jpeds.2024.114045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.

    Moline, Heidi L / Tannis, Ayzsa / Toepfer, Ariana P / Williams, John V / Boom, Julie A / Englund, Janet A / Halasa, Natasha B / Staat, Mary Allen / Weinberg, Geoffrey A / Selvarangan, Rangaraj / Michaels, Marian G / Sahni, Leila C / Klein, Eileen J / Stewart, Laura S / Schlaudecker, Elizabeth P / Szilagyi, Peter G / Schuster, Jennifer E / Goldstein, Leah / Musa, Samar /
    Piedra, Pedro A / Zerr, Danielle M / Betters, Kristina A / Rohlfs, Chelsea / Albertin, Christina / Banerjee, Dithi / McKeever, Erin R / Kalman, Casey / Clopper, Benjamin R / McMorrow, Meredith L / Dawood, Fatimah S

    MMWR. Morbidity and mortality weekly report

    2024  Volume 73, Issue 9, Page(s) 209–214

    Abstract: Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged < ... ...

    Abstract Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infection with hospitalization was 81% (95% CI = 62%-90%) through 150 days after receipt; post-introduction effectiveness has not been assessed in the United States. In this analysis, the New Vaccine Surveillance Network evaluated nirsevimab effectiveness against RSV-associated hospitalization among infants in their first RSV season during October 1, 2023-February 29, 2024. Among 699 infants hospitalized with acute respiratory illness, 59 (8%) received nirsevimab ≥7 days before symptom onset. Nirsevimab effectiveness was 90% (95% CI = 75%-96%) against RSV-associated hospitalization with a median time from receipt to symptom onset of 45 days (IQR = 19-76 days). The number of infants who received nirsevimab was too low to stratify by duration from receipt; however, nirsevimab effectiveness is expected to decrease with increasing time after receipt because of antibody decay. Although nirsevimab uptake and the interval from receipt of nirsevimab were limited in this analysis, this early estimate supports the current nirsevimab recommendation for the prevention of severe RSV disease in infants. Infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.
    MeSH term(s) Infant ; Child ; Humans ; United States/epidemiology ; Respiratory Syncytial Virus Vaccines ; Seasons ; Respiratory Syncytial Virus, Human ; Respiratory Syncytial Virus Infections/epidemiology ; Respiratory Syncytial Virus Infections/prevention & control ; Hospitalization ; Respiratory Tract Infections/epidemiology ; Antibodies, Monoclonal, Humanized
    Chemical Substances nirsevimab (VRN8S9CW5V) ; Respiratory Syncytial Virus Vaccines ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7309a4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024.

    Edens, Chris / Clopper, Benjamin R / DeVies, Jourdan / Benitez, Alvaro / McKeever, Erin R / Johns, Dylan / Wolff, Bernard / Selvarangan, Rangaraj / Schuster, Jennifer E / Weinberg, Geoffrey A / Szilagyi, Peter G / Dawood, Fatimah S / Radhakrishnan, Lakshmi / Quigley, Christina / Sahni, Leila C / Halasa, Natasha / Stewart, Laura S / McMorrow, Meredith L / Whitaker, Brett /
    Zerr, Danielle M / Avadhanula, Vasanthi / Williams, John V / Michaels, Marian G / Kite-Powell, Aaron / Englund, Janet A / Staat, Mary Allen / Hartnett, Kathleen / Moline, Heidi L / Cohen, Adam L / Diaz, Maureen

    MMWR. Morbidity and mortality weekly report

    2024  Volume 73, Issue 7, Page(s) 149–151

    MeSH term(s) Child ; Humans ; Adolescent ; United States/epidemiology ; Pneumonia, Mycoplasma/epidemiology ; Pandemics ; COVID-19/epidemiology ; Antibodies, Bacterial
    Chemical Substances Antibodies, Bacterial
    Language English
    Publishing date 2024-02-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7307a3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023.

    Tannis, Ayzsa / Englund, Janet A / Perez, Ariana / Harker, Elizabeth J / Staat, Mary Allen / Schlaudecker, Elizabeth P / Halasa, Natasha B / Stewart, Laura S / Williams, John V / Michaels, Marian G / Selvarangan, Rangaraj / Schuster, Jennifer E / Sahni, Leila C / Boom, Julie A / Weinberg, Geoffrey A / Szilagyi, Peter G / Clopper, Benjamin R / Zhou, Yingtao / McMorrow, Meredith L /
    Klein, Eileen J / Moline, Heidi L

    MMWR. Morbidity and mortality weekly report

    2023  Volume 72, Issue 48, Page(s) 1300–1306

    Abstract: SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) ... ...

    Abstract SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, case-control design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months-4 years during July 1, 2022-September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%-60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19-associated ED visits and hospitalization.
    MeSH term(s) Child ; Infant ; United States/epidemiology ; Humans ; Child, Preschool ; COVID-19 Vaccines ; SARS-CoV-2/genetics ; Prospective Studies ; Vaccine Efficacy ; COVID-19/epidemiology ; COVID-19/prevention & control ; Vaccines ; Hospitalization ; RNA, Messenger
    Chemical Substances COVID-19 Vaccines ; Vaccines ; RNA, Messenger
    Language English
    Publishing date 2023-12-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7248a2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.

    Frutos, Aaron M / Price, Ashley M / Harker, Elizabeth / Reeves, Emily L / Ahmad, Haris M / Murugan, Vel / Martin, Emily T / House, Stacey / Saade, Elie A / Zimmerman, Richard K / Gaglani, Manjusha / Wernli, Karen J / Walter, Emmanuel B / Michaels, Marian G / Staat, Mary A / Weinberg, Geoffrey A / Selvarangan, Rangaraj / Boom, Julie A / Klein, Eileen J /
    Halasa, Natasha B / Ginde, Adit A / Gibbs, Kevin W / Zhu, Yuwei / Self, Wesley H / Tartof, Sara Y / Klein, Nicola P / Dascomb, Kristin / DeSilva, Malini B / Weber, Zachary A / Yang, Duck-Hye / Ball, Sarah W / Surie, Diya / DeCuir, Jennifer / Dawood, Fatimah S / Moline, Heidi L / Toepfer, Ariana P / Clopper, Benjamin R / Link-Gelles, Ruth / Payne, Amanda B / Chung, Jessie R / Flannery, Brendan / Lewis, Nathaniel M / Olson, Samantha M / Adams, Katherine / Tenforde, Mark W / Garg, Shikha / Grohskopf, Lisa A / Reed, Carrie / Ellington, Sascha

    MMWR. Morbidity and mortality weekly report

    2024  Volume 73, Issue 8, Page(s) 168–174

    Abstract: In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 ... ...

    Abstract In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
    MeSH term(s) Adolescent ; Adult ; Humans ; Child ; Influenza Vaccines ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Seasons ; Case-Control Studies ; Vaccine Efficacy
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7308a3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top